Skip to main content

Executive Directive 2022-12: Lowering the Cost of Insulin

To: State Department Directors and Autonomous Agency Heads
From: Governor Gretchen Whitmer

According to the Center for Disease Control, more than 10 percent of Michiganders have diagnosed diabetes, and they shoulder more than double the medical expenses of those who do not have diabetes. Nearly 3,000 deaths a year in Michigan are attributed to diabetes. 

Insulin, the most prescribed treatment for diabetes, is a century-old, life-saving drug that 
hundreds of thousands of Michiganders need to survive. In the United States, insulin costs 
nearly 10 times as much as in other countries, and 1 in 3 diabetics routinely make 
impossible choices between purchasing insulin and fulfilling their other basic needs, like 
buying groceries or keeping the heat on.

The egregiously high cost of insulin is unsustainable. My administration is committed to
making insulin available to those who need it at an affordable price.

We have already taken steps to lower health care costs for seniors and those receiving 
health insurance subsidies. Executive Directive 2022-9 ensures that Michiganders receive 
the full extent of the savings made possible by the Inflation Reduction Act (IRA). ED 2022-9 also instructed the Michigan Department of Health and Human Services to continue efforts to decrease the cost of prescription drugs for Michigan Medicaid recipients.

There is more work to be done. The IRA limits health care costs for seniors on Medicare by 
capping the out-of-pocket cost of insulin at $35 a month and total prescription drug costs at 
$2,000 a year. But many Michiganders who need life-saving insulin are not covered by the 
IRA, including the uninsured and those who face large out-of-pocket costs under their 
private insurance plans. While the House of Representatives has voted on legislation to 
extend cost caps, further federal action remains uncertain. 

We cannot wait. We must take immediate action to make insulin affordable for 
Michiganders while creating jobs in the state. We cannot allow the opaque pricing practices 
of drug manufacturers and massive health care corporations to force people to ration or 
forgo insulin just so they can keep a roof over their heads and food on the table. We must 
explore every option to lower costs for consumers.

Acting under sections 1 and 8 of Article 5 of the Michigan Constitution of 1963, I direct the 
following:

1. Departments and agencies covered by this section must review aspects of insulin 
purchasing, distribution, and production within their jurisdictions and identify and 
assess potential opportunities to lower costs for Michiganders who purchase insulin. 
Covered departments must provide a report to the Executive Office of the Governor 
detailing their conclusions about such opportunities no later than December 20, 
2022.
The report must:

(a)      Provide the covered department’s assessment of the following approaches to 
           lower insulin costs:
         
          (1)      Development, in conjunction with a partner or partners, of novel low-cost                                            interchangeable biosimilar insulin or other insulin product for 
                    distribution in Michigan; 
       
          (2)     Production, purchase and/or distribution by the state or by the state in 
                    conjunction with other entities of low-cost interchangeable
                    biosimilar or other insulin products; and

          (3)      Establishment of a Michigan-based insulin manufacturing facility by 
                     the state or by the state in conjunction with other entities, including any 
                     potential sites for such facility.

(b) Supply information about any additional actions that the state could take 
that would, in the view of the covered department, feasibly lower insulin 
costs for consumers; and 

(c) To the extent possible, assess the state resources that would be required to 
undertake each action, the timeline of the action, and potential cost savings to 
the state or to individual consumers.

The covered departments are the Department of Health and Human Services, the 
Department of Insurance and Financial Services, the Department of Labor and 
Economic Opportunity, the Department of Licensing and Regulatory Affairs, the 
Department of Technology, Management, and Budget, and the Department of 
Treasury. The Michigan Economic Development Corporation should provide a report 
and participate in any further study.

2. Following receipt of the reports, the Executive Office of the Governor will convene all 
relevant departments and agencies to further assess actions that the state can take to 
lower the cost of insulin for Michiganders.

3. All departments, committees, commissioners, or officers of this state must give any 
necessary assistance required to implement this directive, so far as is compatible
with their duties and consistent with this order and applicable law. Free access also
must be given to any books, records, or documents in their custody relating to 
matters within the scope of inquiry, study, or review, consistent with applicable law.

This directive is effective immediately.

Thank you for your cooperation in its implementation.

Click to view the full PDF of the executive directive

Media Contact: